Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0400
0.00 (0.00%)
At close: Jun 18, 2026
Adaptimmune Therapeutics Company Description
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom.
The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics plc
| Country | United Kingdom |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 506 |
| CEO | Christopher Hill |
Contact Details
Address: The Innovation Centre Abingdon, OX14 4RY United Kingdom | |
| Phone | 44 12 3543 0000 |
| Website | adaptimmune.com |
Stock Details
| Ticker Symbol | ADAPY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00653A1079 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher James Hill ACA, BA (Hons) | Chief Executive Officer, Chief Financial Officer, Secretary and Director |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder |
| Dr. Juli P. Miller Ph.D. | Vice President of Corporate Affairs and Investor Relations |
| Dana Lynch | Senior Director of Corporate Communications |
| Kimberly Freeman | Vice President of Commercial Planning |
| Laura Gunn | Vice President of Medical Affairs |